Tonix Pharmaceuticals
TNXP
1 hedge funds and large institutions have $421K invested in Tonix Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
90% more capital invested
Capital invested by funds: $221K → $421K (+$200K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$34K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$11K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $375K | +$1.59M | +1 | New |
|
2
Acadian Asset Management
Boston,
Massachusetts
| $46K | – | – | – |
|
|
BFM
3
Boothbay Fund Management
New York
| – | -$7K | – | – |
|
|
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$11K | – | – |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| – | -$6K | – | – |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$11K | – | – |
|
|
7
Vanguard Group
Malvern,
Pennsylvania
| – | -$34K | – | – |
|
8
Victory Capital Management
San Antonio,
Texas
| – | -$1K | – | – |
|
TNXP Hedge Fund Activity: Q4 2019 in Review
1 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q4 2019, worth a combined $421K — up 90% from $221K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new TNXP positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.59M. The largest seller was Vanguard Group, cutting an estimated $34K.
- 1 institutional investor held Tonix Pharmaceuticals (TNXP) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $421K of Tonix Pharmaceuticals stock for Q4 2019, up 90% quarter-over-quarter.
- 1 fund opened new Tonix Pharmaceuticals positions in Q4 2019 and 0 closed out, a net change of +1 holder.
- The largest Tonix Pharmaceuticals buyer in Q4 2019 was Renaissance Technologies, an estimated $1.59M added.
- The largest Tonix Pharmaceuticals seller in Q4 2019 was Vanguard Group, an estimated $34K sold.
Based on aggregated 13F filings for Q4 2019.